Journals / Balkan Medical Journal / 2021 / Cilt: 38 - Sayı: 1

New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study

Pages
34–42
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In a low dose of the 5-MeO-MiPT liver section, compared with normal tissues, the difference in staining was statistically significant (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The hallucinogenic tryptamine analog 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) causes social problems worldwide.
📊
Key Findings & Data:There are several studies on the metabolism; however, not more studies were found in the literature on acute toxicity.Aims: To report the acute toxicity of 5-MeO-MiPT in mice, followed by quantitative toxicological analysis of blood and organs, hystotoxicological and immunohistochemical analysis of tissues and cells.Study design: Animal experimentMethods: In vivo experiments were performed using CD1 adult female mice (n=26).
💡
Conclusion & Impact:In a low dose of the 5-MeO-MiPT liver section, compared with normal tissues, the difference in staining was statistically significant (p
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: The hallucinogenic tryptamine analog 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) causes social problems worldwide. There are several studies on the metabolism; however, not more studies were found in the literature on acute toxicity.Aims: To report the acute toxicity of 5-MeO-MiPT in mice, followed by quantitative toxicological analysis of blood and organs, hystotoxicological and immunohistochemical analysis of tissues and cells.Study design: Animal experimentMethods: In vivo experiments were performed using CD1 adult female mice (n=26). Animals were caged in 4 groups randomly. First group was a control (n=3). Second group was vehicle control (n=3) and injected 150 μL of blank solution (50% dimethyl sulfoxide in saline /0.9% of NaCl). While for acute toxicity experiments, 5-MeO-MiPT was added to a blank solution in order to obtain a dose of 0.27 mg/kg in 150 μL injection (n=10) and the last group were injected 2.7 mg/kg 5-MeO-MiPT in a 150 μL injection (n=10). Quantitative toxicological analysis, hystotoxicological and immunohistochemical analysis were performed.Results: In the toxicological analysis, 5-MeO-MiPT was found negative in biological samples which were control, vehicle control, and 0.27 mg/kg dose mice groups. 5-MeO-MiPT was found 2.7-13.4 ng/mL in blood, 11-29 ng/g in kidney, 15.2-108.3 ng/g in liver, and 1.5-40.6 ng/g in the brain in 2,7 mg/kg injected group. In a low dose of the 5-MeO-MiPT liver section, compared with normal tissues, the difference in staining was statistically significant (p

🔖

Cite This Article

AYDOĞDU, M., AKGÜR, S. A., AÇIKGÖZ, E., GÜVEN, Ü., ALTUNCI, Y. A., DÜZAĞAÇ, F., ATASOY, A., DAĞLIOĞLU, N. (2022). New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study. Balkan Medical Journal, Cilt: 38 - Sayı: 1, 34–42. https://ajindex.com/articles/460784

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Soussan C, Kjellgren A. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. Int J Drug Policy 2016
  2. [Crossref] 2. Liechti M. Novel psychoactive substances (designer drugs): Overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 2015
  3. w14043.doi: 10.4414/smw.2015.14043. [Crossref] 3. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007
  4. [Crossref] 4. Deluca P, Davey Z, Corazza O, Furia LD, Farre M, Flesland LH, et al. Identifying emerging trends in recreational drug use
  5. outcomes from the Psychonaut Web Mapping Project. Prog NeuroPsychopharmacology Biol Psychiatry 2012
  6. [Crossref] 5. Hondebrink L, Nugteren-van Lonkhuyzen JJ, Van Der Gouwe D, Brunt TM. Monitoring new psychoactive substances (NPS) in the Netherlands: Data from the drug market and the Poisons Information Centre. Drug Alcohol Depend 2015
  7. [Crossref] 6. Corazza O, Assi S, Malekianragheb S, Beni MN, Bigdeli I, Aslanpour Z, et al. Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. Int J Drug Policy 2014
  8. [Crossref] 7. Göl E, Çok I. New psychoactive substances in Turkey: Narcotics cases assessed by the Council of Forensic Medicine between 2016 and 2017 in Ankara, Turkey. Forensic Sci Int 2019
  9. [Crossref] 8. Hill SL, Thomas SHL. Clinical toxicology of newer recreational drugs. Clin Toxicol. 2011
  10. [Crossref] 9. Araújo AM, Carvalho F, Bastos M de L, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 2015
  11. [Crossref] 10. Shulgin A, Shulgin A. TIHKAL. The Continuation.
  12. 1st ed. Berkeley, CA: Dan Joy
  13. Tittarelli R, Mannocchi G, Pantano F, Romolo F. Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol 2014
  14. [Crossref] 12. Brandt SD, Martins CPB. Analytical methods for psychoactive N,N-dialkylated tryptamines. TrAC - Trends Anal Chem 2010
  15. [Crossref] 13. Grafinger KE, Hädener M, König S, Weinmann W. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug Test Anal 2018
  16. [Crossref] 14. Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R et al. Combined intoxication with m